Sarcoma  >>  Halaven (eribulin mesylate)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Halaven (eribulin mesylate) / Eisai
ACTRN12611001074987: Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Completed
3
450
 
Eisai Limited, Eisai Limited
Soft tissue sarcoma
 
 
NCT01327885 / 2010-024483-17: Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Completed
3
452
Europe, Canada, US, RoW
Eribulin mesylate 1.4 mg/m^2 intravenous, Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
Eisai Inc.
Soft Tissue Sarcoma
01/15
08/16
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas

Recruiting
3
333
US
INT230-6, Eribulin, Trabectedin, Pazopanib
Intensity Therapeutics, Inc., Premier Research Group plc
Sarcoma,Soft Tissue
12/27
12/28

Download Options